It can be expected that this tracer has the potential to overcome current limitations obtained with [99mTc]Tc-PSMA-I&S and thus might pave the way towards a broader future use of PSMA-targeted RGS in the therapy of patients with biochemical recurrent PCa. Here, FOLH1 is linked to posterior cortical atrophy.